Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of PPARgamma and combined agonists on the urinary tract of rats and other species.

Literature DB >> 16049269

Effects of PPARgamma and combined agonists on the urinary tract of rats and other species.

Samuel M Cohen¹.

Abstract

Entities: Gene Species

Mesh：

Substances：
PPAR gamma

Year: 2005 PMID： 16049269 DOI： 10.1093/toxsci/kfi266

Source DB: PubMed Journal: Toxicol Sci ISSN： 1096-0929 Impact factor: 4.849

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.

Authors: Elizabeth M Garry; John B Buse; Jennifer L Lund; Virginia Pate; Til Stürmer
Journal: Diabetes Obes Metab Date: 2017-08-08 Impact factor: 6.577

2. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Authors: Richard M Turner; Chun S Kwok; Chen Chen-Turner; Chinedu A Maduakor; Sonal Singh; Yoon K Loke
Journal: Br J Clin Pharmacol Date: 2014-08 Impact factor: 4.335

Review 3. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Authors: Cristina Bosetti; Valentina Rosato; Danilo Buniato; Antonella Zambon; Carlo La Vecchia; Giovanni Corrao
Journal: Oncologist Date: 2013-01-23

Review 4. Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

Authors: Jean-Luc Faillie; Pierre Petit; Jean-Louis Montastruc; Dominique Hillaire-Buys
Journal: Drug Saf Date: 2013-09 Impact factor: 5.606

5. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Authors: James D Lewis; Assiamira Ferrara; Tiffany Peng; Monique Hedderson; Warren B Bilker; Charles P Quesenberry; David J Vaughn; Lisa Nessel; Joseph Selby; Brian L Strom
Journal: Diabetes Care Date: 2011-04 Impact factor: 19.112

10. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.

Authors: Victoriano Romero; Charles Peyton; Ian Gray; Ashok Hemal; Ryan Terlecki
Journal: BMC Urol Date: 2014-01-25 Impact factor: 2.264

Effects of PPARgamma and combined agonists on the urinary tract of rats and other species.

1. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.

2. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Review 3. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Review 4. Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

5. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

6. Cohort study of pioglitazone and cancer incidence in patients with diabetes.

7. Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside.

8. Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

9. The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

10. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.